Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...

Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...

VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful improvement in progression-free survival ...

Topline results from the VERITAC-2 study showed that Arvinas-partnered vepdegestrant was able to extend progression-free survival (PFS) compared to the older degrader fulvestrant in a subset of HR ...

Those readouts include the VERITAC-2 trial of protein degrader vepdegestrant in second-line oestrogen receptor-positive metastatic breast cancer – the first key data from a drug Pfizer sees as ...

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arvinas Holding Company (ARVN – Research ...

Naughty Dog and Sony revealed The Last of Us Part 2 Remastered for PC with a new trailer during The Game Awards, but there's not much to glean in terms of differences for the PC release. It's all ...

STRASBOURG, France; MONTREAL, Canada; BOSTON, MA, USA I March 20, 2025 I Domain Therapeutics (“Domain” or “the Company”), the GPCR experts harnessing deep receptor biology to develop breakthrough ...

1 Imaging of prostate-specific membrane antigen with positron emission tomography. 2 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.4.2024. 3 NIH Common Cancer ...